GSK sued by inventors of Relenza anti-flu drug

GlaxoSmithKline IS being sued by the Australian inventors of its controversial flu treatment Relenza, who accuse the giant drug maker of failing to properly promote the product.

The Melbourne-based biotech group Biota, which licensed Relenza in 1990 to what was then Glaxo, says it has been driven to the courts after two years of fruitless negotiations with GSK. The product failed to live up to its early promise and had sales last year of less than £10m, despite being approved in 70 countries.

"Relenza was a breakthrough influenza drug that had great potential but it was effectively abandoned at birth," Biota's chief executive, Peter Molloy, said. The company says GSK breached the terms of its licensing deal by failing to launch Relenza in a number of countries, by dropping further studies that may have widened its use, and by not pursuing fully ways to improve the inhaler used for taking the drug. It is demanding unspecified damages, which could total up to $100m (£56m).

GSK said it was surprised by Biota's lawsuit but would not comment further.

The high hopes for Relenza began to falter when the National Institute for Clinical Excellence, the NHS's arbiter of value for money, ruled that the drug would only marginally improve the treatment of flu and should be prescribed only in very limited circumstances. It was a ruling that infuriated Sir Richard Sykes, then chairman of Glaxo Wellcome, so much that he threatened to move the company's headquarters to the US.

Biota is aggrieved that Relenza was sidelined after the merger of Glaxo Wellcome with SmithKline Beecham to create GSK in 2000. GSK has been arguing in private that it pulled applications to launch the drug as a prevention for flu after it became clear it would not get approval in the US.

Relenza was discovered by Biota scientists in 1989 and was the first in a new generation of anti-flu drugs, called neuraminidase inhibitors, which are effective against both major strains of influenza.

However, the fact that it has to be used with an inhaler put it at an immediate disadvantage to a rival pill from Roche, the Swiss pharmaceuticals giant.

Arts and Entertainment
musicBand's first new record for 20 years has some tough acts to follow
peopleAt least it's for a worthwhile cause
A new app has been launched that enables people to have a cuddle from a stranger
voicesMaybe the new app will make it more normal to reach out to strangers
Liam Payne has attacked the media for reporting his tweet of support to Willie Robertson and the subsequent backlash from fans
peopleBut One Direction star insists he is not homophobic
Life and Style
healthFor Pure-O OCD sufferers this is a reality they live in
Life and Style
Sexual health charities have campaigned for the kits to be regulated
healthAmerican woman who did tells parents there is 'nothing to be afraid of'
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Trainee / Experienced Recruitment Consultants

£20000 - £25000 per annum + OTE £40,000: SThree: SThree are a global FTSE 250 ...

Trainee Recruitment Consultant - Soho

£20000 - £25000 per annum + OTE £40000: SThree: As a Recruitment Consultant, y...

Trainee Recruitment Consultants - Banking & Finance

£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...

Quantitative Risk Manager

Up to £80000: Saxton Leigh: My client, a large commodities broker, is looking ...

Day In a Page

A roller-coaster tale from the 'voice of a generation'

Not That Kind of Girl:

A roller-coaster tale from 'voice of a generation' Lena Dunham
London is not bedlam or a cradle of vice. In fact it, as much as anywhere, deserves independence

London is not bedlam or a cradle of vice

In fact it, as much as anywhere, deserves independence
Vivienne Westwood 'didn’t want' relationship with Malcolm McLaren

Vivienne Westwood 'didn’t want' relationship with McLaren

Designer 'felt pressured' into going out with Sex Pistols manager
Jourdan Dunn: Model mother

Model mother

Jordan Dunn became one of the best-paid models in the world
Apple still coolest brand – despite U2 PR disaster

Apple still the coolest brand

Despite PR disaster of free U2 album
Scottish referendum: The Yes vote was the love that dared speak its name, but it was not to be

Despite the result, this is the end of the status quo

Boyd Tonkin on the fall-out from the Scottish referendum
Manolo Blahnik: The high priest of heels talks flats, Englishness, and why he loves Mary Beard

Manolo Blahnik: Flats, Englishness, and Mary Beard

The shoe designer who has been dubbed 'the patron saint of the stiletto'
The Beatles biographer reveals exclusive original manuscripts of some of the best pop songs ever written

Scrambled eggs and LSD

Behind The Beatles' lyrics - thanks to Hunter Davis's original manuscript copies
'Normcore' fashion: Blending in is the new standing out in latest catwalk non-trend

'Normcore': Blending in is the new standing out

Just when fashion was in grave danger of running out of trends, it only went and invented the non-trend. Rebecca Gonsalves investigates
Dance’s new leading ladies fight back: How female vocalists are now writing their own hits

New leading ladies of dance fight back

How female vocalists are now writing their own hits
Mystery of the Ground Zero wedding photo

A shot in the dark

Mystery of the wedding photo from Ground Zero
His life, the universe and everything

His life, the universe and everything

New biography sheds light on comic genius of Douglas Adams
Save us from small screen superheroes

Save us from small screen superheroes

Shows like Agents of S.H.I.E.L.D are little more than marketing tools
Reach for the skies

Reach for the skies

From pools to football pitches, rooftop living is looking up
These are the 12 best hotel spas in the UK

12 best hotel spas in the UK

Some hotels go all out on facilities; others stand out for the sheer quality of treatments